抑郁症治疗的新靶点和新策略

被引:17
作者
王真真
张有志
宫泽辉
李云峰
机构
[1] 军事医学科学院毒物药物研究所
基金
国家高技术研究发展计划(863计划);
关键词
抑郁症; 抗抑郁药;
D O I
暂无
中图分类号
R964 [精神药理学];
学科分类号
0710 ; 071006 ;
摘要
目前临床上使用的抗抑郁药物虽然疗效较好,但起效慢、治疗不彻底和易复发,因此迫切需要寻找疗效更为理想的抗抑郁药物和治疗手段。近年来,在对抑郁症的研究中发现了许多新的治疗靶点,除了经典的对单胺能神经递质调节作用的优化外,还包括对非单胺能神经递质、神经可塑性的调节以及局部脑区刺激等。本文将围绕这些新靶点以及以这些新靶点为依据开发的抗抑郁药物和治疗手段的研究进展予以综述,以期为进一步研发药物或发现新靶点提供一定的思路和依据。
引用
收藏
页码:364 / 370
页数:7
相关论文
共 28 条
[1]   Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist [J].
Phelps, Laura E. ;
Brutsche, Nancy ;
Moral, Jazmin R. ;
Luckenbaugh, David A. ;
Manji, Husseini K. ;
Zarate, Carlos A., Jr. .
BIOLOGICAL PSYCHIATRY, 2009, 65 (02) :181-184
[2]  
Lack of tolerance to anxiolysis and withdrawal symptoms in mice repeatedly treated with AC-5216, a selective TSPO ligand[J] . Atsuko Kita,Tomoko Kinoshita,Hitoshi Kohayakawa,Kiyoshi Furukawa,Akinori Akaike.Progress in Neuropsychopharmacology & Biological Psychiatry . 2009 (6)
[3]  
Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression[J] . Michael Liebrenz,Rudolf Stohler,Alain Borgeat.World Journal of Biological Psychiatry . 2009 (4_2)
[4]  
Case Report: Excellent Response to Long-Term Higher Dose Single Olanzapine in a Case of Recurrent Brief Depression[J] . J. De la Fuente.Pharmacopsychiatry . 2008 (04)
[5]  
In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor[J] . Leah Aluisio,Brian Lord,Ann J. Barbier,Ian C. Fraser,Sandy J. Wilson,Jamin Boggs,Lisa K. Dvorak,Michael A. Letavic,Bruce E. Maryanoff,Nicholas I. Carruthers,Pascal Bonaventure,Timothy W. Lovenberg.European Journal of Pharmacology . 2008 (1)
[6]  
Depression in Parkinson’s disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation[J] . Ticyana Moralez da Silva,Renato Puppi Munhoz,Cristiano Alvarez,Katya Naliwaiko,ágata Kiss,Roberto Andreatini,Anete Curte Ferraz.Journal of Affective Disorders . 2008 (2)
[7]  
Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients[J] . John P. Feighner,Lev Sverdlov,Joseph Hlavka,Gabriela Nicolau,Kenneth Cartwright,Jeffrey S. Freed.International Clinical Psychopharmacology . 2008 (1)
[8]  
High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder[J] . Raymond W. Lam.International Clinical Psychopharmacology . 2007
[9]  
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine[J] . Stuart A. Montgomery,Siegfried Kasper.International Clinical Psychopharmacology . 2007 (5)
[10]  
Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050[J] . Amanda M. Shaw,Mona Boules,Yiqun Zhang,Katrina Williams,Jessica Robinson,Paul R. Carlier,Elliott Richelson.European Journal of Pharmacology . 2007 (1)